Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer

Lenvatinib is approved for the first-line treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day, but its high toxicity often necessitates dose reductions and interruptions. To clarify the efficacy and safety of the reduced dose-initiation of lenv...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Yomi Nakashima, Ichiro Horie, Haruka Arimori, Mayu Ueda, Shinpei Nishikido, Yuta Nakamura, Keita Nakaji, Tetsuro Niri, Ayaka Sako, Ai Haraguchi, Toshiyuki Ikeoka, Satoru Akazawa, Akie Moriuchi, Misa Imaizumi, Toshiro Usa, Atsushi Kawakami
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	The Japan Endocrine Society 2025-12-01
Seri Bilgileri:	Endocrine Journal
Konular:	lenvatinib tyrosine kinase inhibitor radioiodine thyroid cancer
Online Erişim:	https://www.jstage.jst.go.jp/article/endocrj/72/12/72_EJ25-0251/_html/-char/en
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Real-world clinical experience of reduced-dose initiation of lenvatinib in Japanese patients with radioiodine-refractory differentiated thyroid cancer

Benzer Materyaller